Loading...
In patients with asymptomatic severe aortic stenosis, early transcatheter aortic valve replacement (TAVR) was previously shown to be superior to clinical surveillance in an industry-funded, randomized trial, due to a reduction in unplanned cardiovascular hospitalizations. A new post hoc analysis examines whether outcomes varied by patient age.
Patient age showed no overall interaction with the primary composite end point (unplanned cardiovascular hospitalization, stroke, or death); with stroke; or with hospitalization specifically for heart failure (HF).
Despite the lack of a significant interaction, TAVR’s advantage over clinical surveillance with respect to stroke was greatest in the youngest subgroup (65–69 years; 5-year …